Antibiotic developer & sender of occasional AMR newsletters. Antibiotics are the #FireExtinguishersOfMedicine! 💊🧯⚕️
#StopSuperbugs #AMRSOS
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by John Rex
Transferable exclusivity vouchers (TEV) in EU: Coming soon!
Dear All: EMA today hosted an exciting webinar in which they gave a heads-up on the work they have done to create concrete requirements for the upcoming TEVs (TDEVs, Transferrable Data Exclusivity Vouchers) for novel antibacterial agents. The recording and slides from the webinar will be released soon (within a few days, I think); I will provide just some highlights from today.
OHAMR: Transmission-focused call opens 18 Nov 2026 with EUR 31m budget
Dear All, OHAMR (European Partnership on One Health AMR), the successor to the JPIAMR program, have announced the 2nd call in their plan to fund €253 million of AMR research over 10 years. This next call is constructed around the theme of “Transmission.” It opens on 18 Nov 2026 with a budget of EUR 31m for projects in any of 3 research areas: Topic 1: Model AMR transmission dynamics to predict the risk of AMR emergence and spread to support decision-making of public authorities.
Dear All: As a way to pressure test your candidate compounds, PACE (Pathways to Antimicrobial Clinical Efficacy) and UKHSA (the UK Health Security Agency) have collaborated to release five new contemporary antimicrobial resistance (AMR) strain panels: The five panels contain 145 bacterial strains isolated within the last five years.
Dear All: We need to make Pull incentives work! On this theme, our first topic for today is an opportunity for organizations to sign a letter of support for PASTEUR. This letter is co-led by the AMR Action Fund, BIO, Cystic Fibrosis Foundation, Infectious Diseases Society of America and Partnership to Fight Infectious Diseases.
CARB-X: 2nd 2026 application call; 5x impact of CARB-X funding!
Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: Direct-acting therapeutics for infections caused by Gram-negative bacteria “Proposals must target the development of agents for the treatment of Gram-negative priority pathogens” (see our Bugs & Drugs page).
#AMRSOS! The (human) cost of AMR: Data from 19 countries in Asia
Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality associated with severe infections in 19 Asian countries during the period Sep 2022 to Feb 2025. Here are the links you need: (the primary paper): Mo Y, Hao X, Ding Y et al. Severe health-care-associated infections and antimicrobial resistance in an Asian Surveillance Network (ACORN-HAI): A multicentre, prospective cohort study.
Milken webinar: Innovative financing models for antimicrobials
Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the meetings calendar and the list of funding opportunities: TB! PACCARB! Funding for antifungals! Funding for R&D in India! Look closely! Dear All: The AMR Multi-Stakeholder Partnership Platform (AMR MSPP) collaborated with the Milken Institute on 28 May 2026 to host a 90-minute discussion on innovative models for financing antimicrobial development.
AWaRe antibiotic usage – Is 70% Access a good target?
Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public Health.
Forbes JAPAN 公式サイト(フォーブス ジャパン)
自分の成長課題を言語化する苦闘こそが、なぜ成長なのか ニキルは、自分の成長課題を説明できなかった。 私たちはビデオ通話で、私が手がけるあらゆるコーチング支援の軸となる宿題を確認していた。私はクライアントの関係者を十数人ほどインタビューし、聞き取った内容をフィードバック報告書にまとめる。その後、クライアントは3つのリーダーシップ開発課題を書く。各課題は、一人称で書かれた問題提起の見出しと、簡潔な補足説明で構成される。ニキルが私に送ってきた文書は完璧だった。構成は整い、文章には自信があり、句読点の乱れもない。 そこで私は、1つ目について説明してほしいと頼んだ。彼は言葉に詰まった。遠回しに話し、視線を下に落とし、自分の文書を確認するように明らかに読んでいた。最後に彼は打ち明けた。AIが書いたのだ。すべてを。彼はフィードバック報告書を入力し、返ってきた内容を受け入れ、そのままその週の仕事に戻った。...
WHO: Virtual discussion on challenges of evidence generation
Dear All: WHO have announced a very interesting 2-h virtual dialogue on optimal evidence generation across the antibiotic R&D lifecycle! Here are the details you need: When: 31 Aug 2026 (virtual, 2-4p CET): What: A dialogue on challenges such as fragmented regulatory requirements, trade-offs in clinical trial design, and gaps between evidence generated for regulatory approval and the data needed to inform real-world clinical use and stewardship.
Your AI Wrote Your Development Plan. So Whose Growth Is It?
Why the struggle to name your own growth areas is the growth We were on a video call, reviewing the homework that anchors every coaching engagement I run. After I interview a dozen or so of a client's stakeholders and synthesize what I hear into a feedback report, the client writes three leadership development areas: each one a headline problem statement in the first person, followed by a brief elaboration. The document Nikhil sent me was immaculate.
FDA guidance on Substantial Effectiveness; EMA concept paper on Evaluation of Antifungal Agents): Comments sought!
Dear All: Both FDA and EMA have recently released important documents for comment. See below for links and my commentary on the two documents.
WHO Webinars: Pediatric antibiotic R&D and Bacteriophage Community of Practice
Dear All: Two important webinars have just been announced! 22 July (virtual, 2-3.30p CET): The WHO AMR Department and the WHO GAP-r (Global Accelerator for Pediatric Formulations) are hosting an industry dialogue on pediatric and neonatal antibiotic development: The discussion will cover timing of pediatric and neonatal studies, extrapolation from adult data, feasibility of trial designs in children and neonates, and variability in regulatory expectations across jurisdictions.
CDC: Funding opportunities (1 each) in US, Africa, and Asia
John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.
PACCARB returns! 16 June 2026 virtual meeting
Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) is being revived at a 16 June 2026 virtual meeting! Here are the links you need: 19 May 2026 Federal Register notice DHHS webpage about the meeting Date and time: 16 June 2026, 12.30-3.30p ET From the DHHS webpage, we have these notes regarding the meeting: “The 27th PACCARB public meeting will be virtual on June 16, 2026.
EUR 20m funding for next-gen diagnostics for LRTIs (Novo Nordisk Foundation)
John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.
Limits on measuring the impact of rapid antimicrobial susceptibility testing (AST)
Dear All (and with thanks to Arjun Srinivasan for co-authoring this wonkish newsletter — prepare yourself! Know also that there is a parallel 27 May 2026 newsletter entitled “Economic modeling of the value of rapid diagnostics” that discusses the use of modeling to estimate the value of diagnostics in general): Driven by ongoing work to encourage use as part of good medical practice and stewardship, discussions of the value of diagnostics have been increasingly prominent in past issues of...
BARDA seeks info on Phase 2+ antifungals for Candida and Aspergillus
Dear All: As discussed in prior newsletters, BARDA is constantly working to ensure it has adequate medical countermeasures (MCMs) for a variety of possible threats.
CARB-X seeks two Assistant Directors of External Affairs
John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.
Forbes JAPAN 公式サイト(フォーブス ジャパン)
自部門を上手く運営することから企業全体をリードすることへの転換は、ほとんどの幹部が直面する最も困難な変化だ。そこに到達できる人は少ない。 プラナブ氏は現実を受け入れようとしなかった。 コーチング契約を開始して3カ月が経ち、私たちは彼の同僚12人から集めたステークホルダーのフィードバックを振り返るために座っていた。フィードバックは一貫しており、お世辞にも良いものではなかった。同僚たちは彼を優秀だが縄張り意識が強いと評した。部下たちは彼をチームを守る存在だが、より広い組織に対しては盲目的だと呼んだ。上司たちは彼がスケールしていないと述べた。 プラナブ氏は、彼と同じ立場にある数十人のシニア幹部から聞いてきた言葉で反論した。 彼らは私の足を引っ張る。彼らは私のチームが何をしているか理解していない。私たちの目標は本当には一致していない。システムが私たちを対立させている。 彼の言うことは、どれも正確には間違っていなかった。ただ、要点を見逃していただけだ。 パターン...
DTR Gram-negative infections: Are new antibiotics making a difference?
Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be a long, wonkish, but VERY important note! Get coffee! Get to a calm place! Clear your head! Read on!), Provoked by a recent paper on the idea of DTR (Difficult-to-Treat Resistance) by Walker et al. (from the group led by Sameer Kadri at the NIH Clinical Center, full details on the paper are below), we are today going to visit the intersection of a set of intertwined themes.
Por qué tantos grandes ejecutivos fracasan cuando les toca pensar como dueños de la empresa Original
Liderazgo John Rex El límite no suele estar en la capacidad ni en la experiencia: aparece al quedar encerrados en el propio organigrama, aferrados al equipo y sin asumir costos inmediatos para empujar resultados colectivos. Asesoré a 47 ejecutivos de Amazon a lo largo de los años, y ahí advertí un patrón con más claridad que en cualquier otro lugar. No porque Amazon fuera una excepción, sino porque mi muestra era lo bastante amplia como para que esos patrones salieran a la vista.
Nine Years Coaching Amazon Executives: Why Senior Leaders Plateau
The shift from running your team well to leading the enterprise is the hardest one most executives will ever face. Few get there. We were three months into his coaching engagement, sitting together to debrief the stakeholder feedback I’d gathered from twelve of his colleagues. The feedback was consistent, and it wasn’tflattering. His peers described him as brilliant but territorial. His directs called him protective of his team but blind to the broader organization.
AMR Science-Policy Symposia (ESCMID 2026): Smart policies for lean times
Dear All: ESCMID Global once again held an afternoon of sessions focused on the intersection of AMR-related science and policy. With an overall theme of “Smart policies for lean times,” the well-attended afternoon comprised a pair of workshops, a plenary session, and a networking reception (I’ll also note that there was a related integrated workshop [“Aligning research and policy to unlock antibiotic innovation”, supported by GSK] that preceded the afternoon but I was unable to attend it).
Wellcome Leap: $50m for gut-sparing approaches to antibiotic delivery
Dear All: I’ve just learned of a funding call from Wellcome Leap entitled “Focused antibiotics.” The thesis of the call is that the resistance arises (at least in part) when the gut microbiome is exposed incidentally to an antibiotic intended for an infection elsewhere in body (e.g., the lungs).
Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct is due to Patricia and Robert; all the mistakes are mine!), This wonkish note has a short, simple version above my signature and then a longer version below by signature.
AMR Surveillance Data Challenge – Vivli 2026 Call for Projects!
Dear All, I’ve written before about the Vivli data challenge (2024 edition, 2025 edition) and am pleased to be able to say that there is a 2026 challenge! Here are the links you need: The data challenge overview’s home webpage The 20 Oct 2024 newsletter co-authored with Patricia Bradford that gives insights on how to approach the challenge In brief, the 2026 edition now has 13 surveillance datasets (see list below my signature) and the overall goal remains promotion of utilization of the...
GO-Dx: Global One Health Diagnostics Access Compact
Dear All, Building on the concepts of the January 2016 Industry-led Davos Declaration on action on AMR (website;.pdf declaration; yes, it really has been 10 years since the declaration!), we now have the launch of GO-Dx, the Global One Health Diagnostics Access Compact.
The language of AMR: The power of metaphor
Dear All, Acronyms and jargon fill our daily scientific lives but can be impenetrable to newcomers. A great example is the title of the 20 Feb 2020 newsletter: “Language Matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs.
BBC Discovery: Great podcast series on AMR!
John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.
Antimicrobial Effectiveness: The strategic economic value of antibiotics
Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the quiet safety net of modern medicine. They underpin everything from routine infections to cancer treatment and surgery. They also support animal health and food production. Antimicrobial Effectiveness (AME, the ability of these medicines to remain efficacious and accessible for appropriate use) is a foundational component of the systems that sustain modern societies.
WHO: New TPPs for antibacterial agents
Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes of a drug) as guides for developers (see the 1 Sep 2019 newsletter for the original call for input and the link to the final set of TPPs).
EMA: “Regulatory sandboxes” to explore approval pathways
Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is that I heard a fascinating talk on the idea of “regulatory sandboxes” during the recent BEAM-AMR meeting.
CARB-X seeks new Chief of R&D (fully remote, worldwide)
Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research & Development! Given CARB-X’s role as the world’s leading public-private partnership accelerating the early-stage development of innovative products to treat, prevent, and diagnose life-threatening bacterial infections, and its current investment levels (approx.
FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval
Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for co-authoring this newsletter), In a position paper recently released in the New England Journal of Medicine, we have notice of a shift in FDA policy from a default expectation of two pivotal trials to a default of one pivotal trial + confirmatory evidence for approvals. Although two trials might still be needed for some approvals, the shift is in the starting default.
Workshop on diagnostics: Can we drive use by making value visible?
Dear All (and with thanks to Robert Skov for co-authoring this newsletter AND with a wonkish alert for this complicated topic for which a compelling narrative is only now starting to unfold … so, get your coffee and be ready to follow the links as you read on!), While we often talk in this newsletter about the need for new antimicrobials, the parallel narrative of the need to have (and use) diagnostics is equally pressing as these are the tools that enable the antibiotic stewardship programs...
PASTEUR (v2.0) reintroduced in the US Congress!
Dear All, I’m delighted to be able to say that PASTEUR 2026 was (re)introduced into the US Congress this week! It’s an improved version relative to the version introduced into the prior 3 sessions of the US Congress (see below for discussion of that), so I think we can safely call it “PASTEUR v2.0” as well as by its more official name of PASTEUR 2026.
The global funding pipeline, 2017-2023: A review
Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of the global funding pipeline for 2017-2023! Here are the links you need: The new paper and its primary data source: Paper: Czaplewski L, Lamichhane U, Sudbrak R, Hennessy A, Ogilvie LA, and Piddock LJV. An overview of global public and philanthropic investments into antibacterial therapeutics (2017-23). The Lancet Microbe. DOI: 10.1016/j.lanmic.2025.101288 .
FDA RFPs: Susceptibility breakpoints and external controls for invasive fungal infections
John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.
Two new oral drugs for gonorrhea!
Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As a marvelous way to end the last year, the US FDA announced on 12 Dec 2025 its approval of two new oral therapies for gonorrhea, thus addressing the priority pathogen lists of both WHO (High priority) and CDC (Urgent) due to the rise in resistant infections. Achieving this has been a huge lift for reasons we’ll discuss below.
CARB-X Novel Chemistry for AMR Challenge
Dear All, Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two funding calls during 2026 (April and then Q4) and (ii) that a theme focused on finding new chemical scaffolds will be part of both calls. Applications to these target-based therapeutics funding calls will require defined chemistry plans based on literature evidence suggesting that novel chemistry scaffolds with activity against validated bacterial targets can be found.
The threat of mirror bacteria: Ongoing conversations (2025 wrap-up)
Dear All, Regular readers will be aware of the global conversation now happening around the threat arising from the potential to create viable organisms that are (at a molecular level) the mirror images of existing organisms.
Natural product-inspired antibiotics: 1943-2025
Dear All, In a paper that is clearly a labor of love (1,032 references!), Mark Butler and Robert Capon have summarized the history of 217 natural product-inspired antibiotics across 16 classes from penicillin to fidaxomicin! Here are the links you need: Butler MS, Capon RJ. Natural product inspired antibiotics approved for human use – 1943 to 2025. Natural Product Reports. 2026. DOI:10.1039/d5np00067j.
Horizon Europe Work Programme 2026-2027: Calls of interest!
Dear All, Our colleagues in Europe have been busy! Along with yesterday’s announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe Work Programme 2026-2027.
Pull incentives in Europe: TEVs to be included in legislative update
Dear All, There are more details yet to come, but the EU Council (“the Council”) and the EU Parliament (EP) yesterday announced an agreement on the update to the EU General Pharmaceutical Legislation that includes transferable exclusivity vouchers (TEVs or TEEVs, depending on your preferred abbreviation).
Phage therapy: Further notes related to the recent TATFAR paper
John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.
Phage therapy: Regulatory perspectives from TATFAR
Dear All, Integrating perspectives from EC HERA, EMA, Health Canada, Norway, UK MHRA, US FDA, and US NIH, the Transatlantic Task Force on AMR (TATFAR)’s Phage Working Group have just published a detailed summary of information on phage therapy with particular focus on its regulatory aspects. Here are the links you need: [key paper for this newsletter] Moon, K., Coxon, C., Årdal, C. et al. Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance.
Forbes JAPAN 公式サイト(フォーブス ジャパン)
経営幹部が自信を美徳、疑いを欠点として扱うとき、イノベーションが犠牲になる。 優秀な人材が集まる会議室にいながら、実質的な思考がほとんど生まれない。いつも同じ声が支配し、スライドは法廷弁論のように守られ、質問は攻撃のように感じられる。決断は既定の結論として提示される。 それは自信のように見え、能力のように感じられる。しかし実際に目にしているのは、静かで組織化された一種の崇拝だ。確信という名の崇拝である。このような文化では、イノベーションは大きな音を立てて死ぬのではない。それは、賢すぎ、速すぎ、そして正しくあることに固執するリーダーたちの重圧の下で窒息するのだ。 戦略文書よりも速く変化する世界において、組織内で最も危険な信念は、おそらくあなたが最も誇りに思っているものだろう——すでに答えを知っているという思い込みだ。...
Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on AMR across India for 2024. The report is the eighth since AMRSRN started publishing such reports in 2017; the report for 2024 is here and links to all the prior reports are here.
AMR in India: A possible global future unless we act now!
Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on AMR across India for 2024. The report is the eighth since AMRSRN started publishing such reports in 2017; the report for 2024 is here and links to all the prior reports are here.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with John
Contact John, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack